GD-11 for Injection in the Treatment of Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 980 participants.

Also called NCT06299579

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 980 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06299579
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06299579. Randomized; triple masking; primary purpose treatment. Start 2024-02-29 (actual); primary completion 2025-02-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GD-11 for Injection in the Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
GD-11 for injection test group
Intervention (Drug)
Placebo control group
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Jiangsu Wangao Pharmaceutical Co. ltd (class: not stated)

Record details

Record id
cardio:ct-nct06299579
Content hash
a4dd077ba695aa4da15101659adf4d09b32df7d921f860c3aa946e65bdcdfec9